Clinical Trials Logo

Clinical Trial Summary

This study is a Phase Ib/II, open-label, multicenter clinical trial. Here, the Study Phase Ib is mainly to evaluate safety of Toripalimab + Cetuximab in treatment of relapsed or metastatic HNSCC failing first-line platinum-based regimen and determine the recommended Phase II dose (RP2D); the Study Phase II is mainly to evaluate efficacy and safety of the combination in treatment of relapsed or metastatic HNSCC failing first-line platinum-based regimen.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04856631
Study type Interventional
Source Shanghai Junshi Bioscience Co., Ltd.
Contact Xiaofei Tang, Bachelor
Phone 18502921630
Email [email protected]
Status Recruiting
Phase Phase 1/Phase 2
Start date February 2, 2021
Completion date November 30, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT03667482 - Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer Phase 1
Completed NCT02083692 - Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling Phase 0
Active, not recruiting NCT02282371 - Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC) Phase 1
Recruiting NCT03138070 - A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719 N/A
Active, not recruiting NCT02159508 - Intensive Nutrition Counselling in Patients With Head and Neck Cancer N/A
Active, not recruiting NCT02252042 - Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) Phase 3
Terminated NCT01790516 - Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer N/A
Completed NCT00574977 - Safety Study of Modified Vaccinia Virus to Cancer Phase 1
Completed NCT00592371 - Head and Neck Cancer Screening and Serum Repository N/A
Recruiting NCT04389632 - A Study of SGN-B6A in Advanced Solid Tumors Phase 1
Recruiting NCT02485548 - Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer Phase 3
Terminated NCT01326923 - Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer Phase 2
Not yet recruiting NCT03975270 - Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma ) Phase 2
Recruiting NCT04187872 - LITT and Pembrolizumab in Recurrent Brain Metastasis Phase 1
Recruiting NCT02327468 - Inovio TRT-001: Telomerase DNA Immunotherapy in Breast, Lung, and Pancreatic Cancers Phase 1
Recruiting NCT01351103 - A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Phase 1
Terminated NCT00260598 - LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer Phase 2
Completed NCT02163057 - Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma Phase 1/Phase 2